Literature DB >> 8287062

Expression of CYP1A1 and CYP1A2 genes in human liver.

H Schweikl1, J A Taylor, S Kitareewan, P Linko, D Nagorney, J A Goldstein.   

Abstract

Immunoblot analysis of human livers using a monospecific antibody to rat CYP1A2 section demonstrated that the expression of CYP1A2 protein is highly variable in human liver. Quantitative PCR analysis was then employed to examine the interindividual variability of both CYP1A1 and CYP1A2 mRNAs in human liver. Hepatic content of CYP1A2 mRNA correlated significantly with levels of CYP1A2 protein as analysed by immunoblot analysis (r = 0.58; p < 0.01). CYP1A2 mRNA content varied > 40-fold among individuals while CYP1A1 content varied > 20-fold. CYP1A2 mRNA was higher than CYP1A1 mRNA (approximately two to 30-fold) in livers of different individuals. The individual with the highest CYP1A1 and CYP1A2 mRNA amounts was a current smoker, but mRNA expression in two other smokers was within the range observed among nonsmokers. The expression of the two CYP1A mRNAs correlated highly (r = 0.72; p < 0.0005) when smokers were included, but the correlation was less significant (r = 0.62; p < 0.05) in nonsmokers. We amplified a full-length CYP1A2 cDNA clone by PCR from a liver which expressed extremely low amounts of CYP1A2 protein. Sequence analysis indicated that exon 4 was missing in this clone, but no other sequence changes were found. PCR analysis demonstrated that both the normally spliced mRNA and abnormally spliced mRNA could be detected in all human livers examined, but the normally spliced mRNA was more abundant than the splice variant. Therefore, sequence changes in the coding region of CYP1A2 did not account for the poor expression of CYP1A2 in this individual.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8287062     DOI: 10.1097/00008571-199310000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  31 in total

1.  Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.

Authors:  David R Plowchalk; Karen Rowland Yeo
Journal:  Eur J Clin Pharmacol       Date:  2012-01-19       Impact factor: 2.953

2.  Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma.

Authors:  Yu-Jing Zhang
Journal:  World J Hepatol       Date:  2010-03-27

3.  N-Acetyl-2-Aminofluorene (AAF) Processing in Adult Rat Hepatocytes in Primary Culture Occurs by High-Affinity Low-Velocity and Low-Affinity High-Velocity AAF Metabolite-Forming Systems.

Authors:  Katherine S Koch; Tom Moran; W Thomas Shier; Hyam L Leffert
Journal:  Toxicol Sci       Date:  2018-05-01       Impact factor: 4.849

Review 4.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

5.  Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.

Authors:  Evelyn D Lobo; Carol Robertson-Plouch; Tonya Quinlan; Quan Hong; Richard F Bergstrom
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 6.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study.

Authors:  Li Tao; Yong-Bing Xiang; Kenneth K Chan; Renwei Wang; Yu-Tang Gao; Mimi C Yu; Jian-Min Yuan
Journal:  Int J Cancer       Date:  2011-06-21       Impact factor: 7.396

8.  Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism.

Authors:  H C Liang; H Li; R A McKinnon; J J Duffy; S S Potter; A Puga; D W Nebert
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

9.  Gene expression and immunochemical localization of major cytochrome P450 drug-metabolizing enzymes in bovine nasal olfactory and respiratory mucosa.

Authors:  Varsha Dhamankar; Mahfoud Assem; Maureen D Donovan
Journal:  Inhal Toxicol       Date:  2015-11-16       Impact factor: 2.724

10.  Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.

Authors:  Dimiter Terziivanov; Kristina Bozhinova; Velislava Dimitrova; Ivanka Atanasova
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.